Notably, the SHOX2, RASSF1A, and PTGER4 methylation panel in plasma achieved a high sensitivity of 82.5% in stage I and 90.5% in stage II lung cancer patients, respectively. The gene discussed is RASSF1; the disease is lung carcinoma.